netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Dexamethasone found 27 matches

Formulary items 15 matches
   
Open monograph to display formulary status BNF Category
  Dexamethasone Endocrine system - Glucocorticoid therapy - 06.03.02
  Dexamethasone 0.05% with framycetin 0.5% ear drops  (Sofradex®) Ear, nose and oropharynx - Anti-inflammatory preparations - 12.01.01
  Dexamethasone 0.05%, framycetin sulf. 0.5%, gramicidin 0.005% eye drops  (Sofradex) Eye - Corticosteroids - 11.04.01
  Dexamethasone 0.1% eye drops  (Maxidex®) Eye - Corticosteroids - 11.04.01
  Dexamethasone 0.1% Preservative-free Eye - Corticosteroids - 11.04.01
  Dexamethasone 0.1% with neomycin 0.5% spray  (Otomize®) Ear, nose and oropharynx - Anti-inflammatory preparations - 12.01.01
  Dexamethasone 3.3mg in 1ml and 6.6mg in 2ml
(injection )
Endocrine system - Glucocorticoid therapy - 06.03.02
  Dexamethasone 700 microgram intravitreal implant  (Ozurdex®) Eye - Corticosteroids - 11.04.01
  Dexamethasone Phosphate Musculoskeletal and joint diseases - Local corticosteroids injections - 10.01.02.02
  Dexamethasone with Neomycin and Polymyxin B sulphate  (Maxitrol®) Eye - Corticosteroids - 11.04.01
  Cytotoxic Drug Carfilzomib  (Kyprolis®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Daratumumab  (Darzalex®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Isatuximab Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Lenalidomide Malignant disease and immunosuppression - Lenalidomide, pomalidomide, and thalidomide - 08.02.04
  Cytotoxic Drug Panobinostat Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Alert (Oct 2014): Dexamethasone 4 mg/ml injection (Organon Laboratories Limited): reformulation with changes in name, concentration, storage conditions, and presentation (06.03.02)
link in drug section NICE TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (11.04.01)
link in drug section NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.02)
link in drug section NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.01)
link in drug section NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (08.02.04)
link in drug section NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma (08.02.04)
link in drug section NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (08.01.05)
link in drug section NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (08.01.05)
link in drug section NICE TA824: Dexamethasone intravitreal implant for treating diabetic macular oedema (11.04.01)
link in drug section NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (08.01.05)
link in drug section NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (08.01.05)
link in drug section NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (08.01.05)


 

netFormulary